icone plus
Contact Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité DUPIXENT (dupilumab).
See also
Décision d'accès précoce
14/11/2024
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
3czxtfDbBSyQ51RZ
Listen
